Effect of ivabradine on cardiac arrhythmias: Antiarrhythmic or proarrhythmic?
Atrial fibrillation
Coronary artery disease
HCN channels
Heart failure
Ivabradine
Ventricular arrhythmias
Journal
Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
19
01
2021
revised:
09
03
2021
accepted:
10
03
2021
pubmed:
20
3
2021
medline:
11
2
2022
entrez:
19
3
2021
Statut:
ppublish
Résumé
Cardiac arrhythmias are a major source of mortality and morbidity. Unfortunately, their treatment remains suboptimal. Major classes of antiarrhythmic drugs pose a significant risk of proarrhythmia, and their side effects often outweigh their benefits. Therefore, implantable devices remain the only truly effective antiarrhythmic therapy, and new strategies of antiarrhythmic treatment are required. Ivabradine is a selective heart rate-reducing agent, an inhibitor of hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels, currently approved for treatment of coronary artery disease and chronic heart failure. In this review, we focus on the clinical and basic science evidence for the antiarrhythmic and proarrhythmic effects of ivabradine. We attempt to dissect the mechanisms behind the effects of ivabradine and indicate the focus of future studies.
Identifiants
pubmed: 33737235
pii: S1547-5271(21)00231-9
doi: 10.1016/j.hrthm.2021.03.020
pii:
doi:
Substances chimiques
Cardiovascular Agents
0
Ivabradine
3H48L0LPZQ
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1230-1238Informations de copyright
Copyright © 2021 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.